Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Johnson & Johnson recently announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as ...

A greater number of patients treated with subcutaneous guselkumab induction and maintenance vs placebo achieved clinical remission and endoscopic response at 48 weeks in the Phase 3 GRAVITI study1 ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear ...

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

You may report side effects to Health Canada at 1-866-234-2345. Before using guselkumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product ...

Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model.

About TREMFYA® (guselkumab) Developed by Johnson & Johnson, TREMFYA® is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the ...